keyword
MENU ▼
Read by QxMD icon Read
search

rekhtman

keyword
https://www.readbyqxmd.com/read/28884744/pulmonary-large-cell-neuroendocrine-carcinoma-with-adenocarcinoma-like-features-napsin-a-expression-and-genomic-alterations
#1
Natasha Rekhtman, Catherine M Pietanza, Joshua Sabari, Joseph Montecalvo, Hangjun Wang, Omar Habeeb, Kyuichi Kadota, Prasad Adusumilli, Charles M Rudin, Marc Ladanyi, William D Travis, Philippe Joubert
Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a highly aggressive malignancy, which was recently found to comprise three major genomic subsets: small cell carcinoma-like, non-small cell carcinoma (predominantly adenocarcinoma)-like, and carcinoid-like. To further characterize adenocarcinoma-like subset, here we analyzed the expression of exocrine marker napsin A, along with TTF-1, in a large series of LCNECs (n=112), and performed detailed clinicopathologic and genomic analysis of napsin A-positive cases...
September 8, 2017: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/28799111/erratum-to-micropapillary-and-or-solid-histologic-subtype-based-on-pre-treatment-biopsy-predicts-local-recurrence-after-thermal-ablation-of-lung-adenocarcinoma
#2
Song Gao, Seth Stein, Elena N Petre, Waleed Shady, Jeremy C Durack, Carole Ridge, Prasad S Adusumilli, Natasha Rekhtman, Stephen B Solomon, Etay Ziv
No abstract text is available yet for this article.
August 10, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/28771603/expression-of-pd-l1-and-other-immunotherapeutic-targets-in-thymic-epithelial-tumors
#3
Kathryn C Arbour, Jarushka Naidoo, Keith E Steele, Ai Ni, Andre L Moreira, Natasha Rekhtman, Paul B Robbins, Joyson Karakunnel, Andreas Rimner, James Huang, Gregory J Riely, Matthew D Hellmann
INTRODUCTION: The thymus is a critical organ for the development of the adaptive immune system and thymic epithelial tumors (TETs; thymomas and thymic carcinomas) are often associated with auto-immune paraneoplastic conditions. However, the immunobiology of TETs is not well described. An evaluation of the tumor microenvironment, with particular focus on expression of immunotherapeutic targets, may facilitate and prioritize development of immunotherapy strategies for patients with TETs...
2017: PloS One
https://www.readbyqxmd.com/read/28770314/micropapillary-and-or-solid-histologic-subtype-based-on-pre-treatment-biopsy-predicts-local-recurrence-after-thermal-ablation-of-lung-adenocarcinoma
#4
Song Gao, Seth Stein, Elena N Petre, Waleed Shady, Jeremy C Durack, Carole Ridge, Prasad Adusumilli, Natasha Rekhtman, Stephen B Solomon, Etay Ziv
BACKGROUND: To investigate whether histologic subtyping from biopsies can predict local recurrence after thermal ablation for lung adenocarcinoma. METHODS: Patients treated with CT-guided thermal ablation for lung adenocarcinoma that had pre-ablation needle biopsy with analysis of histologic components were identified. Age, gender, smoking status, treatment indication (primary stage 1 tumor versus salvage), histologic subtype, ground-glass radiographic appearance, tumor size, ablation modality, and ablation margin were evaluated in relation to time to local recurrence (TTLR)...
August 2, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/28686497/immunohistochemistry-of-pulmonary-biomarkers-a-perspective-from-members-of-the-pulmonary-pathology-society
#5
Erik Thunnissen, Timothy Craig Allen, Julien Adam, Dara L Aisner, Mary Beth Beasley, Alain C Borczuk, Philip T Cagle, Vera Luiza Capelozzi, Wendy Cooper, Lida P Hariri, Izidor Kern, Sylvie Lantuejoul, Ross Miller, Mari Mino-Kenudson, Teodora Radonic, Kirtee Raparia, Natasha Rekhtman, Sinchita Roy-Chowdhuri, Prudence Russell, Frank Schneider, Lynette M Sholl, Ming Sound Tsao, Marina Vivero, Yasushi Yatabe
The use of immunohistochemistry for the determination of pulmonary carcinoma biomarkers is a well-established and powerful technique. Immunohistochemisty is readily available in pathology laboratories, is relatively easy to perform and assess, can provide clinically meaningful results very quickly, and is relatively inexpensive. Pulmonary predictive biomarkers provide results essential for timely and accurate therapeutic decision making; for patients with metastatic non-small cell lung cancer, predictive immunohistochemistry includes ALK, (ROS1, EGFR in Europe), and programmed death ligand-1 (PD-L1) testing...
July 7, 2017: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/28639854/rapid-on-site-evaluation-of-endobronchial-ultrasound-guided-transbronchial-needle-aspirations-for-the-diagnosis-of-lung-cancer-a-perspective-from-members-of-the-pulmonary-pathology-society
#6
Deepali Jain, Timothy Craig Allen, Dara L Aisner, Mary Beth Beasley, Philip T Cagle, Vera Luiza Capelozzi, Lida P Hariri, Sylvie Lantuejoul, Ross Miller, Mari Mino-Kenudson, Sara E Monaco, Andre Moreira, Kirtee Raparia, Natasha Rekhtman, Anja Christiane Roden, Sinchita Roy Chowdhuri, Gilda da Cunha Santos, Erik Thunnissen, Giancarlo Troncone, Marina Vivero
CONTEXT: - Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) has emerged as a very useful tool in the field of diagnostic respiratory cytology. Rapid on-site evaluation (ROSE) of EBUS-TBNA not only has the potential to improve diagnostic yield of the procedure but also to triage samples for predictive molecular testing to guide personalized treatments for lung cancer. OBJECTIVE: - To provide an overview of the current status of the literature regarding ROSE of EBUS-TBNA in the diagnosis of lung cancer...
June 22, 2017: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/28625636/prognostic-impact-of-ttf-1-expression-in-patients-with-stage-iv-lung-adenocarcinomas
#7
Juliana B Schilsky, Ai Ni, Linda Ahn, Sutirtha Datta, William D Travis, Mark G Kris, Jamie E Chaft, Natasha Rekhtman, Matthew D Hellmann
OBJECTIVES: Thyroid transcription factor 1 (TTF-1) is routinely tested in the diagnostic evaluation of suspected lung cancers, is commonly expressed by lung adenocarcinomas, and may modulate lung cancer biology. We examined the role of TTF-1 as a predictive and prognostic marker in patients with advanced lung adenocarcinomas. MATERIALS AND METHODS: We analyzed clinical, pathologic, and molecular features, treatments received, and overall survival obtained from the medical records of 479 consecutive patients at a single site with stage IV lung adenocarcinomas and evaluable TTF-1 expression...
June 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28505004/a-subset-of-malignant-mesotheliomas-in-young-adults-are-associated-with-recurrent-ewsr1-fus-atf1-fusions
#8
Patrice Desmeules, Philippe Joubert, Lei Zhang, Hikmat A Al-Ahmadie, Christopher D Fletcher, Efsevia Vakiani, Deborah F Delair, Natasha Rekhtman, Marc Ladanyi, William D Travis, Cristina R Antonescu
Malignant mesothelioma (MM) is a rare, aggressive tumor often associated with asbestos exposure and characterized by complex genetic abnormalities, including deletions of chromosome 22. A gene fusion involving EWSR1 and YY1 gene on 14q32 has been reported in 2 patients over the age of 60 with peritoneal MM. However, the incidence of EWSR1 rearrangements in MM and the spectrum of its fusion partners remain unknown. We recently encountered 2 MM cases with EWSR1-ATF1 fusions and sought to investigate the prevalence and clinicopathologic features associated with this abnormality...
July 2017: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/28336552/prospective-comprehensive-molecular-characterization-of-lung-adenocarcinomas-for-efficient-patient-matching-to-approved-and-emerging-therapies
#9
Emmet J Jordan, Hyunjae R Kim, Maria E Arcila, David Barron, Debyani Chakravarty, JianJiong Gao, Matthew T Chang, Andy Ni, Ritika Kundra, Philip Jonsson, Gowtham Jayakumaran, Sizhi Paul Gao, Hannah C Johnsen, Aphrothiti J Hanrahan, Ahmet Zehir, Natasha Rekhtman, Michelle S Ginsberg, Bob T Li, Helena A Yu, Paul K Paik, Alexander Drilon, Matthew D Hellmann, Dalicia N Reales, Ryma Benayed, Valerie W Rusch, Mark G Kris, Jamie E Chaft, José Baselga, Barry S Taylor, Nikolaus Schultz, Charles M Rudin, David M Hyman, Michael F Berger, David B Solit, Marc Ladanyi, Gregory J Riely
Tumor genetic testing is standard of care for patients with advanced lung adenocarcinoma, but the fraction of patients who derive clinical benefit remains undefined. Here, we report the experience of 860 patients with metastatic lung adenocarcinoma analyzed prospectively for mutations in >300 cancer-associated genes. Potentially actionable genetic events were stratified into one of four levels based upon published clinical or laboratory evidence that the mutation in question confers increased sensitivity to standard or investigational therapies...
June 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28196596/chemosensitive-relapse-in-small-cell-lung-cancer-proceeds-through-an-ezh2-slfn11-axis
#10
Eric E Gardner, Benjamin H Lok, Valentina E Schneeberger, Patrice Desmeules, Linde A Miles, Paige K Arnold, Andy Ni, Inna Khodos, Elisa de Stanchina, Thuyen Nguyen, Julien Sage, John E Campbell, Scott Ribich, Natasha Rekhtman, Afshin Dowlati, Pierre P Massion, Charles M Rudin, John T Poirier
Small cell lung cancer is initially highly responsive to cisplatin and etoposide but in almost every case becomes rapidly chemoresistant, leading to death within 1 year. We modeled acquired chemoresistance in vivo using a series of patient-derived xenografts to generate paired chemosensitive and chemoresistant cancers. Multiple chemoresistant models demonstrated suppression of SLFN11, a factor implicated in DNA-damage repair deficiency. In vivo silencing of SLFN11 was associated with marked deposition of H3K27me3, a histone modification placed by EZH2, within the gene body of SLFN11, inducing local chromatin condensation and gene silencing...
February 13, 2017: Cancer Cell
https://www.readbyqxmd.com/read/28094897/cytology-assessment-can-predict-survival-for-patients-with-metastatic-pancreatic-neuroendocrine-neoplasms
#11
Carlie S Sigel, Huimin Guo, Keith M Sigel, Ming Zhang, Natasha Rekhtman, Oscar Lin, David S Klimstra, Achim A Jungbluth, Laura K Tang
BACKGROUND: Histological features and Ki-67 index have known usefulness in predicting prognosis and guiding therapy among patients with metastatic pancreatic neuroendocrine neoplasms. Fine-needle aspiration may offer advantages for Ki-67 assessment because the technique obtains highly cellular, well-preserved specimens with the potential for broader tumor sampling. In the current study, the authors evaluated concordance for grade and differentiation between concurrent core needle biopsy and cytology preparations...
March 2017: Cancer
https://www.readbyqxmd.com/read/27987102/characteristics-of-mesenteric-lymphadenitis-in-comparison-with-those-of-acute-appendicitis-in-children
#12
COMPARATIVE STUDY
Itai Gross, Yael Siedner-Weintraub, Shir Stibbe, David Rekhtman, Daniel Weiss, Natalia Simanovsky, Dan Arbell, Saar Hashavya
Mesenteric lymphadenitis (ML) is considered as one of the most common alternative diagnosis in a child with suspected acute appendicitis (AA). In this retrospective study, patients diagnosed with ML (n = 99) were compared in terms of demographic, clinical, and laboratory findings to patients diagnosed with AA (n = 102). This comparison was applied for both lymph nodes smaller and larger than 10 mm. When compared to patients with AA, patients with ML had significantly longer duration of symptoms prior to emergency department (ED) presentation (2...
February 2017: European Journal of Pediatrics
https://www.readbyqxmd.com/read/27977506/management-of-pediatric-acute-mastoiditis-in-israel-nationwide-survey-among-otorhinolaryngologists-and-emergency-pediatricians
#13
Sharon Tamir Ovnat, Tal Marom, David Rekhtman, Michal Luntz
INTRODUCTION: Acute mastoiditis (AM) is a medical emergency that mandates prompt diagnosis and treatment. Nevertheless, its management often differs between otorhinolaryngologists (ORLs) and pediatricians (PEDs) working in emergency departments. We sought to characterize the similarities and differences between management protocols of these 2 disciplines. MATERIALS AND METHODS: A voluntary electronic questionnaire, including 17 items pertaining to pediatric AM management, was sent to all the 20 otorhinolaryngology and their corresponding pediatric emergency departments nationwide...
December 13, 2016: Pediatric Emergency Care
https://www.readbyqxmd.com/read/27969491/ps01-24-clinical-outcomes-of-patients-with-pulmonary-large-cell-neuroendocrine-carcinoma-characterized-by-next-generation-sequencing-topic-medical-oncology
#14
Joshua Sabari, Charles Rudin, Natasha Rekhtman
No abstract text is available yet for this article.
November 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27863924/successful-use-of-afatinib-after-erlotinib-induced-pneumonitis-in-a-patient-with-epidermal-growth-factor-receptor-mutant-lung-cancer
#15
Christopher D Jakubowski, Andrew J Plodkowski, Jason C Chang, Natasha Rekhtman, Afsheen Iqbal, Paul K Paik, Helena A Yu
No abstract text is available yet for this article.
January 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/27830957/health-related-quality-of-life-and-patient-reported-outcomes-of-ofatumumab-plus-fludarabine-and-cyclophosphamide-versus-fludarabine-and-cyclophosphamide-in-the-complement-2-trial-of-patients-with-relapsed-cll
#16
Tadeusz Robak, Krzysztof Warzocha, K Govind Babu, Yaroslav Kulyaba, Kazimierz Kuliczkowski, Kudrat Abdulkadyrov, Javier Loscertales, Iryna Kryachok, Janusz Kłoczko, Grygoriy Rekhtman, Wojciech Homenda, Jerzy Z Błoński, Astrid McKeown, Chai-Ni Chang, Vasudha Bal, Steen Lisby, Ira V Gupta, Sebastian Grosicki
Chronic lymphocytic leukemia (CLL) is an incurable disease. Quality of life during treatment and periods of subsequent remission is therefore vital. Health-related quality of life (HRQoL) was compared in relapsed CLL during and after treatment with ofatumumab combined with fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide alone. The European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 v3 and QLQ-CLL16 were used to assess HRQoL in this open-label, phase 3 study. Improvements in prespecified domains of patient-reported outcomes (Global Health Status [GHS]/HRQoL and B symptom scores) were recorded in both treatment arms after three cycles and were sustained after 18 months of follow-up...
July 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27825636/cabozantinib-in-patients-with-advanced-ret-rearranged-non-small-cell-lung-cancer-an-open-label-single-centre-phase-2-single-arm-trial
#17
Alexander Drilon, Natasha Rekhtman, Maria Arcila, Lu Wang, Andy Ni, Melanie Albano, Martine Van Voorthuysen, Romel Somwar, Roger S Smith, Joseph Montecalvo, Andrew Plodkowski, Michelle S Ginsberg, Gregory J Riely, Charles M Rudin, Marc Ladanyi, Mark G Kris
BACKGROUND: RET rearrangements are found in 1-2% of non-small-cell lung cancers. Cabozantinib is a multikinase inhibitor with activity against RET that produced a 10% overall response in unselected patients with lung cancers. To assess the activity of cabozantinib in patients with RET-rearranged lung cancers, we did a prospective phase 2 trial in this molecular subgroup. METHODS: We enrolled patients in this open-label, Simon two-stage, single-centre, phase 2, single-arm trial in the USA if they met the following criteria: metastatic or unresectable lung cancer harbouring a RET rearrangement, Karnofsky performance status higher than 70, and measurable disease...
December 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27819763/diagnosis-of-acute-cellular-rejection-and-antibody-mediated-rejection-on-lung-transplant-biopsies-a-perspective-from-members-of-the-pulmonary-pathology-society
#18
Anja C Roden, Dara L Aisner, Timothy Craig Allen, Marie Christine Aubry, Roberto J Barrios, Mary B Beasley, Philip T Cagle, Vera L Capelozzi, Sanja Dacic, Yimin Ge, Lida P Hariri, Sylvie Lantuejoul, Ross A Miller, Mari Mino-Kenudson, Andre L Moreira, Kirtee Raparia, Natasha Rekhtman, Lynette Sholl, Maxwell L Smith, Ming S Tsao, Marina Vivero, Yasushi Yatabe, Eunhee S Yi
CONTEXT: - The diagnosis and grading of acute cellular and antibody-mediated rejection (AMR) in lung allograft biopsies is important because rejection can lead to acute graft dysfunction and/or failure and may contribute to chronic graft failure. While acute cellular rejection is well defined histologically, no reproducible specific features of AMR are currently identified. Therefore, a combination of clinical features, serology, histopathology, and immunologic findings is suggested for the diagnosis of AMR...
March 2017: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/27788046/cytology-specimens-a-goldmine-for-molecular-testing
#19
Natasha Rekhtman, Sinchita Roy-Chowdhuri
No abstract text is available yet for this article.
November 2016: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/27731748/ofatumumab-plus-fludarabine-and-cyclophosphamide-in-relapsed-chronic-lymphocytic-leukemia-results-from-the-complement-2-trial
#20
Tadeusz Robak, Krzysztof Warzocha, K Govind Babu, Yaroslav Kulyaba, Kazimierz Kuliczkowski, Kudrat Abdulkadyrov, Javier Loscertales, Iryna Kryachok, Janusz Kłoczko, Grygoriy Rekhtman, Wojciech Homenda, Jerzy Z Błoński, Astrid McKeown, Michele M Gorczyca, Jodi L Carey, Chai-Ni Chang, Steen Lisby, Ira V Gupta, Sebastian Grosicki
In this multicenter, open-label, phase III study, patients with relapsed chronic lymphocytic leukemia (CLL) were randomized (1:1) to receive ofatumumab plus fludarabine and cyclophosphamide (OFA + FC) or FC alone; the primary endpoint being progression-free survival (PFS) assessed by an independent review committee (IRC). Between March 2009 and January 2012, 365 patients were randomized (OFA + FC: n = 183; FC: n = 182). Median IRC-assessed PFS was 28.9 months with OFA + FC versus 18.8 months with FC (hazard ratio = 0...
May 2017: Leukemia & Lymphoma
keyword
keyword
48941
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"